Patents by Inventor Patrick M. Hughes

Patrick M. Hughes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • toxin formulation
    Patent number: 9050336
    Abstract: Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: June 9, 2015
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Roger K. Aoki, Terrence J. Hunt, Patrick M. Hughes, James N. Chang, Scott M. Whitcup, Michael R. Robinson
  • Botulinum toxin formulation
    Patent number: 9044477
    Abstract: Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: June 2, 2015
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Roger K. Aoki, Terrence J. Hunt, Patrick M. Hughes, James N. Chang, Scott M. Whitcup, Michael R. Robinson
  • Intraocular Formulation
    Publication number: 20150147406
    Abstract: Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 28, 2015
    Inventors: Michael R. Robinson, Wendy M. Blanda, Hui Liu, Scott M. Whitcup, Patrick M. Hughes
  • SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY
    Publication number: 20150104491
    Abstract: The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 16, 2015
    Inventors: Ruiwen Shi, Patrick M. Hughes, James A. Burke, Michael R. Robinson, Hui Liu
  • Hypotensive lipid-containing biodegradable intraocular implants and related methods
    Publication number: 20150099805
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 9, 2015
    Inventor: Patrick M. Hughes
  • Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
    Patent number: 8999397
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: April 7, 2015
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Intraocular drug delivery systems
    Patent number: 8969415
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, Guadalupe Ruiz, Werhner C. Orilla, Scott M. Whitcup, Devin F. Welty, Joan-En Lin, Lon T. Spada
  • Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
    Patent number: 8968766
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Joan-En Lin, Jane-Guo Shiah, Thierry Nivaggioli
  • HYPOTENSIVE LIPID-CONTAINING BIODEGRADABLE INTRAOCULAR IMPLANTS AND RELATED METHODS
    Publication number: 20140371308
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: August 11, 2014
    Publication date: December 18, 2014
    Inventor: Patrick M. Hughes
  • Hypotensive lipid-containing biodegradable intraocular implants and related methods
    Patent number: 8911767
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: December 16, 2014
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Hypotensive lipid-containing biodegradable intraocular implants and related methods
    Patent number: 8900622
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: December 2, 2014
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Intraocular Drug Delivery Systems
    Publication number: 20140341968
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.
    Type: Application
    Filed: August 1, 2014
    Publication date: November 20, 2014
    Inventors: Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, Guadalupe Ruiz, Werhner C. Orilla, Scott M. Whitcup, Lon T. Spada, Devin F. Welty, Joan-En Lin
  • METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION
    Publication number: 20140322206
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Application
    Filed: July 7, 2014
    Publication date: October 30, 2014
    Inventors: Scott M. Whitcup, Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke
  • PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF
    Publication number: 20140314868
    Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 23, 2014
    Inventors: Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon T. Spada, Alazar N. Ghebremeskel
  • INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS
    Publication number: 20140316009
    Abstract: The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 23, 2014
    Applicant: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • BOTULINUM TOXIN FORMULATION
    Publication number: 20140302007
    Abstract: Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
    Type: Application
    Filed: May 8, 2012
    Publication date: October 9, 2014
    Applicant: ALLERGAN, INC.
    Inventors: Wendy M. Blanda, Rober K. Aoki, Terrence J. Hunt, Patrick M. Hughes, James N. Chang, Scott M. Whitcup, Michael R. Robinson
  • Microsphere Drug Delivery System for Sustained Intraocular Release
    Publication number: 20140294986
    Abstract: Disclosed are biodegradable microspheres between 40 ?m and 200 ?m in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (>7 day) release of the drug following administration to the anterior chamber of the eye. Methods for making and using the microspheres to treat an ocular condition are also disclosed.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Applicant: Allergan, Inc.
    Inventors: Hui Liu, Jinping Wan, Patrick M. Hughes
  • PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT
    Publication number: 20140271780
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Allergan, Inc.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Method for treating atrophic age related macular degeneration
    Patent number: 8821870
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: September 2, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke, Scott M. Whitcup
  • Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
    Patent number: 8771745
    Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: July 8, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon T. Spada, Alazar N. Ghebremeskel